Launched by UK DRI at King’s in 2019, the adeno-associated virus (AAV) vector core aims to assist with the design and pre-clinical validation and clinical trials of AAV vectors capable of delivering long lasting, cost effective and safe therapies for neurodegenerative diseases.
In recent years there has been a resurgence in gene therapy efforts that is partly fuelled by the identification and understanding of new gene delivery vectors. AAV is a non-enveloped virus that can be engineered to deliver DNA to target cells, and has attracted a significant amount of attention in the field. Prof Chris Shaw, Group Leader from UK DRI at Kings, leads the team in the generation of gene therapy vectors at the UK DRI.
The team are specialists in the production of high-quality AAV, which they apply the Centre’s research into frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). They also advise UK DRI researchers across the Institute on the development, safety and efficacy testing and production of novel AAV tools.
Find out more about the adeno-associated virus platform in the launch news article.
In December 2021, Prof Shaw and the team raised $80m Series A funding for their spin-out AvaidoBioto develop treatments for Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS, motor neuron disease, MND), with a view to targeting other diseases in the future.
Read about the new spin-out AvaidoBio in this news article.